SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Xencor (XNCR)
XNCR 14.37+5.0%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (39)10/28/2014 9:48:48 PM
From: fitzdad55  Read Replies (1) of 136
 
An interesting move by Dahiyat. Because the ph2a trial for XmaB5871 was blinded we don't know the results yet. (Dahiyat stated results will be disclosed end of year.) It does seem to mark a more intensive focus on mAb therapies for diseases with unmet needs. RA is certainly a crowded and competitive space and this may prove to be a very smart move for Xencor in the longer term. Of course, I'm still wondering what the Ph2a results will reveal when they are announced.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News